These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9192757)

  • 61. [Resistance to activated protein C--a novel cause of thrombophilia].
    Cycowitz Z; Seligsohn U; Zivelin A; Eldor A
    Harefuah; 1995 Jul; 129(1-2):1-5, 80. PubMed ID: 7557699
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
    Kraus M; Zander N; Fickenscher K
    Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V.
    Lu D; Kalafatis M; Mann KG; Long GL
    Blood; 1996 Jun; 87(11):4708-17. PubMed ID: 8639840
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
    Liu-Chen LY; Chen C; Phillips CA
    Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.
    Thorelli E; Kaufman RJ; Dahlbäck B
    J Biol Chem; 1998 Jun; 273(26):16140-5. PubMed ID: 9632668
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors.
    Giri TK; Yamazaki T; Sala N; Dahlbäck B; de Frutos PG
    Blood; 2000 Jul; 96(2):523-31. PubMed ID: 10887114
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Coagulation factor V: an old star shines again.
    Rosing J; Tans G
    Thromb Haemost; 1997 Jul; 78(1):427-33. PubMed ID: 9198191
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regulation of platelet factor Va-dependent thrombin generation by activated protein C at the surface of collagen-adherent platelets.
    Briedé JJ; Tans G; Willems GM; Hemker HC; Lindhout T
    J Biol Chem; 2001 Mar; 276(10):7164-8. PubMed ID: 11113137
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors.
    Regan LM; Stearns-Kurosawa DJ; Kurosawa S; Mollica J; Fukudome K; Esmon CT
    J Biol Chem; 1996 Jul; 271(29):17499-503. PubMed ID: 8663474
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
    Ts'ao C; Neofotistos D; Oropeza M; Vahabinejad S; Finn WG
    Am J Hematol; 1997 Mar; 54(3):214-8. PubMed ID: 9067500
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
    Bernardi F; Faioni EM; Castoldi E; Lunghi B; Castaman G; Sacchi E; Mannucci PM
    Blood; 1997 Aug; 90(4):1552-7. PubMed ID: 9269773
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors.
    Matsumoto T; Nogami K; Shima M
    J Thromb Haemost; 2014 Sep; 12(9):1503-12. PubMed ID: 25041532
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factor V.
    Rosing J; Tans G
    Int J Biochem Cell Biol; 1997 Oct; 29(10):1123-6. PubMed ID: 9438374
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system.
    Shen L; He X; Dahlbäck B
    Thromb Haemost; 1997 Sep; 78(3):1030-6. PubMed ID: 9308749
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Alarcón-Segovia D; Ruiz-Argüelles A
    Blood Coagul Fibrinolysis; 1996 Apr; 7(3):344-8. PubMed ID: 8735142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.
    Dahlbäck B; Hildebrand B
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1396-400. PubMed ID: 8108421
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation.
    Maurissen LF; Thomassen MC; Nicolaes GA; Dahlbäck B; Tans G; Rosing J; Hackeng TM
    Blood; 2008 Mar; 111(6):3034-41. PubMed ID: 18160668
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibition of activated protein C by platelets.
    Jane SM; Mitchell CA; Hau L; Salem HH
    J Clin Invest; 1989 Jan; 83(1):222-6. PubMed ID: 2910909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.